The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center

VernacularTitle:艾曲泊帕联合环孢素A治疗输血依赖非重型再生障碍性贫血疗效分析
Author: Yu CHEN ¹ ; Qiang ZHA ; Fei HUANG ; Chun QIAO ; Yan WANG ; Rong WANG ; Jianyong LI ; Wenyi SHEN
Author Information

1. 南京医科大学第一附属医院　江苏省人民医院血液科，南京　210029
Keywords: Eltrombopag; Transfusion-dependent non-severe aplastic anemia; Cyclosporine A; Response
From: Chinese Journal of Internal Medicine 2022;61(4):409-411
CountryChina
Language:Chinese
Abstract: The main purpose of our study was to evaluate the efficacy and safety of eltrombopag plus cyclosporine A (CsA) in transfusion-dependent non-severe aplastic anemia(TD-NSAA). The clinical characteristics of 13 TD-NSAA patients who received initial treatment of eltrombopag plus CsA from 2019 to 2021 were retrospectively analyzed. The 3-month overall hematological response (OR) rate was 12/13. Until the end of follow-up, 12 patients responded, among whom 2 patients reached complete response (CR) and 9 patients reached partial response (PR) and 1 with HR. Paroxysmal nocturnal hemoglobinuria (PNH) developed in one patient at 6 months after treatment. Five of thirteen patients reported mild adverse reactions, which were all manageable. Compared with historical data, the combination of eltrombopag with CsA is an effective regimen in patients with TD-NSAA.